中文

Veracyte falls 54% as its prostate test growth target is cut

By · AI-assisted, human-reviewed and edited · · 15 sources · Fact-checked · 8 min read

Why is Veracyte stock down today?

Veracyte beat third-quarter forecasts, but its main product, the Decipher prostate cancer test, fell short of its own expectations again, and it expects only mid-single-digit revenue growth in 2027 after about 15% this year. The shares fell about 54%, their biggest one-day fall in at least 10 years (Nasdaq closes, our calculation), on a day the S&P 500 fell 4.4%. They were already down more than 40% at the open; no source we found explains the further slide, though the market's fall may have added to it.

What it means

What changed
Veracyte now expects mid-single-digit revenue growth in 2027 and 12,000 to 15,000 more Decipher tests a year, down from about 20,000.
What hasn't changed
Its thyroid test Afirma beat expectations, its 2026 adjusted EBITDA margin outlook holds above 26%, and its 25% long-term margin goal stands.
Next · Late February 2027 (expected)
Fourth-quarter results and the formal 2027 outlook, after the board approves the budget. Veracyte hasn't announced a date.
Move
▼ 54.3%
Price
$52.52 → $24.00
Value lost
~$2.3B
2027 revenue growth
Mid-single digits
Decipher tests added yearly
12–15K (was ~20K)
2027 EBITDA margin
~22% (2026: >26%)

Prices: Official close via Yahoo Finance and CNBC (Nasdaq-listed; Nasdaq's quote page showed a last trade of $23.88), Nov 5, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Closing prices on Nov 5, 2026: the official close, from Yahoo Finance and CNBC (Nasdaq's quote page showed a last trade of $23.88; its closing-price file had not yet posted the day); the day's low was $21.91. The previous close is the official Nov 4 close. Market value uses 80,695,480 common shares on Oct 30 (10-Q cover).

Snapshot at the Nov 5, 2026 close

Enterprise value
$1.6B
Price/sales
3.3×
P/E
15.3×
Price/FCF
12.0×
Revenue growth
+18%
Net cash
$371M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $24.00 (Official close via Yahoo Finance and CNBC (Nasdaq-listed; Nasdaq's quote page showed a last trade of $23.88)); 80.7 million shares (common shares on the cover page of the 10-Q filed Nov 5, 2026). n/m = not meaningful (e.g. negative earnings).

What happened

Veracyte sells gene-based cancer tests. Decipher Prostate brought in 61% of third-quarter revenue and the Afirma thyroid test 34% (our calculation). The quarter beat forecasts on Wednesday, but Decipher fell short again and the first look at 2027 was far weaker than this year.

  • Revenue rose 15% to $151.8 million and adjusted earnings per share (EPS) were $0.51, against FactSet estimates of $147.1 million and $0.41, per MT Newswires. Adjusted EPS was flat from a year earlier. Net income of $31.5 million included a $10.4 million tax benefit; pretax income was $21.1 million against $18.9 million (our calculation: net income less the tax benefit in each period, with no normal tax rate applied). Operating income fell to $16.6 million from $22.9 million (10-Q).
  • Decipher volume was about 29,900 tests, some 1,000 fewer than Veracyte expected. Its growth has slowed through the year: 24% in the first quarter, 17% in the second and 12% in the third.
  • Veracyte trimmed its 2026 revenue outlook to $590 million to $593 million from $590 million to $596 million, and testing revenue to $571 million to $573 million from $576 million to $582 million. The new range is below the $593.8 million FactSet consensus, Seeking Alpha reported. It kept its adjusted EBITDA (earnings before interest, tax, depreciation and amortization) margin outlook above 26%.
  • For 2027 it gave a preliminary view: about 10% volume growth, mid-single-digit revenue growth and an adjusted EBITDA margin of about 22%, with the first quarter below that. The board hasn’t yet approved the budget, CEO Marc Stapley said. That falls below prior expectations: Leerink analyst Puneet Souda cited prior consensus revenue growth of 11% and volume growth of 11%, Seeking Alpha reported via TradingView, without identifying the consensus vendor.
  • It reset the number of tests it expects Decipher to add each year to 12,000 to 15,000, with the low end “a reasonable floor for now.” In July, Stapley said the pace “seems to be around 20,000 tests a year, plus or minus 1,000 or so,” and that he saw no reason for the trend to change “in the next couple of years.”
  • The shares fell to about $37 after hours (Investing.com), opened below $30 and closed down about 54% at $24.00 on Thursday, the biggest one-day fall in at least 10 years; the previous worst was 22.5% on July 31, after the second-quarter results. The stock had been up 25% this year through Wednesday (Nasdaq closes, our calculation). The S&P 500 fell 4.4%, Natera 7.0% and Guardant Health 9.0%, while Myriad Genetics, which sells the rival Prolaris prostate test, rose 4.5% after its own results (Yahoo Finance).

Why the market reacted this way

The beat looked back at a quarter. The reset changed the outlook for next year, with slower growth and lower margins together, and it reversed what the CEO had said about the main test three months earlier.

  • Growth and margin fall together. Revenue is heading for 14% to 15% growth this year and mid-single digits next year. The margin goes from above 26% to about 22%, because Veracyte plans to enlarge its urology team by about 30% and spend more on evidence. That is the trade-off: lower margins now to try to restart Decipher’s growth.
  • The Decipher arithmetic changed within a quarter. In July, Stapley saw about 20,000 added tests a year for the next couple of years, and finance chief Rebecca Chambers expected about 31,000 tests in the third quarter and 33,000 in the fourth, and about 20% Decipher revenue growth for the year. Now it is 29,900, a roughly flat fourth quarter and about 16%, which leaves about 4,200 fewer tests in the second half than July’s forecast (our calculation). Adding 12,000 tests would be about 10% growth on this year’s roughly 117,500 (our calculation).
  • Stapley gave three reasons: guideline changes that drove “two years of outsized growth” are wearing off; a 2026 guideline change and more low-risk patients choosing active surveillance (monitoring rather than immediate treatment) without further testing have slowed that group to single digits; and interest in digital pathology tools takes up sales time. He said Decipher is “still taking share.” Those are the company’s explanations, and we found no independent data on orders or share.
  • This was the second disappointment in two quarters. July’s trim of about 1,000 tests was described as primarily affecting low-risk testing. The stock fell 22.5% the next day and had recovered 13% by Wednesday (Nasdaq closes, our calculation).
  • Investors now pay far less for each dollar of sales. At Wednesday’s close, Veracyte’s market value of $4.2 billion was about 7.2 times the midpoint of its 2026 revenue outlook; at $24.00 it is about 3.3 times (our calculation). The value lost, about $2.3 billion, is about four times this year’s revenue, while revenue is still forecast to grow. Most of the fall reflects that lower multiple, which is the market’s judgment about future growth rather than a number Veracyte has reported.
  • Analysts on the call pressed on whether this is the bottom. Leerink analyst Puneet Souda asked “why is this not a structural bleed in volumes that could accelerate further?” Stapley said the second-half trajectory implies about 12,000 additional tests a year and “We feel very confident in that 12,000 number.” UBS analyst Doug Schenkel, whose firm last rated the stock Buy, suggested “10% might be the ceiling” for Decipher in multi-year models; Chambers answered that the wider portfolio is “a double-digit opportunity.” Asked to split the cut between low-risk and other patients, she called it “an exercise in futility.” Souda argued that Veracyte is now becoming a slower-growth company, Seeking Alpha reported. Leerink (Market Perform, from Outperform) now has a $35 target and Needham (Buy) $46, Investing.com reported.

What the sources can’t explain

  • The slide after the open. The stock was down about 31% before the open, at $36.25 (Investing.com), opened below $30 and fell as low as $21.91 before closing at $24.00. We found no new company announcement after the call except the 10-Q, filed at about 8 a.m. It reports no material change in risk factors, but updates the existing thyroid-test patent case with another patent reexamination and summary-judgment motions in October. We found no same-day coverage linking those developments to the stock’s decline. Same-day coverage also cited Leerink’s downgrade and Needham’s target cut alongside the weaker growth outlook, but did not identify a separate catalyst for the slide after the open. We also found no report of a new payer or guideline decision, a rival’s data or forced selling that day.
  • How much of it is the market. Thursday was a bad day for stocks generally: the S&P 500 fell 4.4%, the Nasdaq Composite 5.5%, the SPDR S&P Biotech ETF (XBI) 6.7%, and two diagnostics peers 7% and 9%. Most of Veracyte’s fall came before that selling. It opened at $29.59, down 44% and about 80% of the day’s drop, while the S&P 500 opened little changed and XBI down 1%. From open to close it lost a further 19%, against 4.2% for the S&P 500 and 5.7% for XBI (Yahoo Finance, our calculation). We can’t separate the market’s contribution to that stretch from the company news; Veracyte’s decline was much larger than those index and peer moves.
  • Why the gap produced a fall this large. The preliminary growth outlook is below the prior 11% consensus cited in Seeking Alpha’s account of Leerink analyst Puneet Souda’s note, but the sources don’t break down how much of a 54% fall reflects that gap and how much a broader loss of confidence in the growth story.
  • Whether the slowdown is temporary. Veracyte says growth is normalizing and new evidence could lift it; Leerink’s Souda raised the possibility of a structural decline. Neither can be tested from public data yet. We have not independently checked the NCCN guideline text. Veracyte attributes part of the slowdown to a 2026 change affecting these tests. Separately, The Active Surveillor, a patient-focused newsletter, reported that an October update calls active surveillance “strongly preferred” for eligible low-risk patients; it did not quantify any effect on testing.

Does this change Veracyte’s future?

What did NOT change

Afirma grew revenue 19% and Veracyte raised its growth outlook for that test to about 16%. The business stays profitable: $121.3 million of operating cash flow in nine months and $370.5 million of cash and short-term investments, after paying $150 million for bladder-cancer testing company Convergent Genomics. Veracyte authorized a $100 million buyback and kept its long-term targets of a 25% margin and 80% share and penetration for Decipher. Those are company goals.

What DID change

In July, Veracyte raised its 2026 outlook, assumed about 20% Decipher revenue growth and saw about 20,000 added tests a year; now it assumes about 16% and 12,000 to 15,000, with a lower 2027 margin. It expects its newer tests, Prosigna in breast cancer and bladder products, to matter more in 2028 and beyond than next year.

Our read

Our interpretation is that the fall is mostly a change in what investors will pay for a business whose main growth engine has slowed twice in four months, more than a change in near-term numbers. The company’s account of why is plausible but unverified from outside, and nothing we found fully explains the further slide after the open, though the market’s fall may have added to it. The fourth-quarter results and any low-risk trial readouts are the next evidence.

The other view

Needham analyst Mike Matson kept a Buy rating while cutting his target to $46 from $69 on reduced growth expectations, Investing.com reported. Leerink analyst Puneet Souda moved to Market Perform with a $35 target.

Source: Investing.com: Needham cuts Veracyte stock price target to $46

What to watch next

Late February 2027 (expected)
Fourth-quarter results and the formal 2027 outlook. Veracyte hasn't announced the date; this year's came in late February.
2027 (company estimate)
Phase III studies of Decipher in low-risk prostate cancer, which Veracyte says could begin reporting preliminary findings as early as next year. Its CEO said in July that it doesn't know whether they will read out positively.
Ongoing
Whether Decipher keeps adding about 12,000 tests a year as Veracyte expands its urology team by about 30%, and how much of the $100 million buyback it uses.

Quick questions

What does Decipher Prostate do?

It is a test run on prostate tumor tissue. Veracyte says its molecular tests assess the biology of each patient's tumor to help doctors answer questions about cancer care. It brought in 61% of Veracyte's third-quarter revenue (our calculation).

What is coming up for Veracyte's pipeline in the next 12 months?

As of Nov 4, 2026, Veracyte says phase III studies of Decipher in low-risk prostate cancer could begin reporting preliminary findings as early as 2027, and that full data from the phase III OPTIMA trial of its Prosigna breast cancer test should be published in early 2027. It expects to launch its first UroAmp bladder cancer test application later, in late 2028.

Why does 10% volume growth mean only mid-single-digit revenue growth?

Finance chief Rebecca Chambers said prior-period collections and revenue mix account for the difference. Veracyte has collected about $10.5 million of older payments from Afirma and Decipher so far this year and doesn't guide for them, and it expects its newer Prosigna test to be priced near what it costs to run for now.

About Veracyte: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.